The Longevity FAQ

The longevity field has a public-communication problem: the popular books flatten the uncertainty, the primary literature is inaccessible, and the wellness industry traffics in claims that are five years behind or five decades ahead of the evidence. Ricon's FAQ occupies an unusual and useful niche — a working researcher explaining the field at a level of detail and nuance that neither dumbs down nor blinds. It is one of the few texts you can recommend to a smart non-expert who wants to know what the science actually says.nnThe first key argument is about the complexity of the causal story. Most popular treatments of ageing present a single driving mechanism — Sinclair's epigenetic noise theory, or the oxidative stress hypothesis, or telomere attrition. Ricon treats each as a partial truth in an entangled system. The nine hallmarks of ageing (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication) interact in ways that mean treating any one of them in isolation may miss the larger dynamic. Cellular senescence, for example, depletes NAD+ through CD38 overactivation, which in turn suppresses sirtuins, which in turn accelerates epigenetic drift — a cascade that looks like three separate problems and is actually one.nnThe second and more practical move is the intervention section, which is unusually honest about effect sizes and generalisability limits. Rapamycin extends median lifespan in mice by 23-26% in the NIA trials — the strongest reproducible result across species — but inhibits mTORC2 in chronic use, causing immunosuppression. Acarbose matches those numbers in male mice; its mechanism (reducing postprandial glucose spikes) is well-understood; its translation to humans has not been tested. Calorie restriction clearly improves healthspan markers in monkeys; the maximum lifespan effect is smaller and contested. Ricon refuses to compress the uncertainty.nnWe picked this because it is the most intellectually responsible popular-science treatment of longevity biology currently available on the open web — useful for anyone curious about ageing, investing in biotech, or simply wondering what the supplements they are taking actually do. The unsettling conclusion Ricon leaves you with is that the field is advancing faster than the current evidence base supports — and that the gap is where most of the money currently flows.